We have previously reported the generation of two novel anti-CD109 mAbs by means of hybridoma technology using BxPC-3 human pancreatic cancer cells, a cell line derived from a primary tumour, as the source of immunogen9. This evidence concerns the gene CD109 and pancreatic neoplasm.